CSIMarket Company Name, Ticker, Competitors, else..
 
Intelgenx Technologies Corp   (IGXT)
Other Ticker:  
 
 
Price: $0.1670 $0.00 1.829%
Day's High: $0.1693 Week Perf: 6.98 %
Day's Low: $ 0.16 30 Day Perf: -10.7 %
Volume (M): 33 52 Wk High: $ 0.00
Volume (M$): $ 6 52 Wk Avg: $0.00
Open: $0.16 52 Wk Low: $0.00



 Market Capitalization (Millions $) 29
 Shares Outstanding (Millions) 175
 Employees 30
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Intelgenx Technologies Corp
Intelgenx Technologies Corp is a pharmaceutical company that focuses on the development and manufacturing of innovative drug delivery technologies. They specialize in oral film drug delivery systems, which are dissolvable strips that deliver medication through the mouth. These films offer advantages such as improved bioavailability, faster onset of action, and ease of use. Intelgenx partners with pharmaceutical companies to license and develop new products using their drug delivery technologies. They also have their own pipeline of generic and branded drugs in development. Overall, Intelgenx Technologies Corp aims to improve the effectiveness and convenience of drug delivery methods.


   Company Address: 6420 Abrams Ville Saint Laurent 0 QC
   Company Phone Number: 331-7440   Stock Exchange / Ticker: IGXT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
COLL        2.23% 
MNKD        1.62% 
MRNS        0.62% 
PBYI   -4.63%    
TEVA   -0.24%    
VTRS   -0.56%    
• View Complete Report
   



Vistagen Therapeutics Inc

Breaking down fourth quarter of 2025 performance, VTGNs' made

In its January to March 31 2025 Vistagen Therapeutics Inc Diminishing Returns have expanded at $-0.43 per share, opposite of $-0.18 per share a year before quarter, In the prior quarter VTGN realized $-0.46 per share.

Context Therapeutics Inc

Context Therapeutics Inc declared operating shortfall in the first quarter of 2025

The Major Pharmaceutical Preparations sector reporters continue to analyze the first quarter of 2025 numbers. Now they observe operating shortfall of $-5.529143 million, from the Context Therapeutics Inc , as it hasn't cited any revenue yet, for the own January to March 31 2025 quarter.

Lipella Pharmaceuticals Inc

Redemption of Diminishing Returns at LIPO in the first quarter of 2025 earnings season

For the first quarter of 2025 earnings season company managed to cut its losses on vanishing revenue, where loss per share were at $-0.64 relative to $-1.28 and revenue decreased by -11.304 % to $0.13 million relative to $0.15 million in the comparable quarter a year prior.

Sunshine Biopharma Inc

The company disclosed astonishing double digit revenue improvement, in the financial span ending March 31 2025

For the January to March 31 2025 time-frame Sunshine Biopharma Inc decreased a loss per share of $-0.44 per share compare to $-2.00 a year ago and EPS improved from $-1.11 per share from the previous financial reporting period. The revenue inched up respectably by 18.039 % to $8.90 million from $7.54 million in the comparable financial reporting period a year ago and sequentially Revenue deteriorated by -7.229 % from $9.59 million. Major Pharmaceutical Preparations company's business advanced at higher rate in contrast to the the revenue at almost all of the Major Pharmaceutical Preparations sector contemporaries, in the first quarter of 2025 the most corporations in Major Pharmaceutical Preparations sectors had an average business improvement of 4.50% from the comparable financial reporting period a year ago.

23andme Holding Co

The unpleasant -28.87 % deterioration in revenue at 23andme Holding Co over the financial fourth quarter of 2025

For the fiscal span ending March 31 2025 23andme Holding Co decreased a loss per share of $-1.87 per share compare to $-8.14 a year prior and EPS improved from $-2.01 per share from the prior reporting season. The revenue crumbled by -28.87 % to $46.26 million from $65.03 million in the similar reporting season a year prior and sequentially revenue fell by -22.681 % from $59.83 million. The deterioration of business is in contrast to in proportion to all in all Major Pharmaceutical Preparations sector, which posted a revenue gain meanwhile.







Intelgenx Technologies's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com